Financial Report: Pfizer 2Q

Pfizer 2Q

2Q Revenues: $17.3 billion (+58%)

2Q Earnings: $2.5 billion (+9%)

YTD Revenues: $34.1 million (+56%)

YTD Earnings: $4.5 billion (-10%)

Comments: Revenues in the quarter were favorably impacted by $5.4 billion (most of the 58% revenue bump), due to the addition of the legacy Wyeth products. Biopharmaceutical revenues, which includes Primary Care, Specialty Care, Established Products, Emerging Markets and Oncology, totaled $15.0 billion in the quarter (+49%). Diversified revenues, inclusive of Animal Health, Consumer Healthcare, Nutrition and Capsugel, totaled $2.2 billion compared to $833 million in 2Q09. Lipitor sales were up 5% to $2.8 billion. Lyrica sales were up 21% to $762 million. Celebrex sales were $604 million (+10%). Viagra sales were $491 million (+16%). Xalatan/Xalacom sales were $449 million (+14%). Norvasc sales were down 19% to $422 million due to the loss of exclusivity in Canada. Enbrel sales (outside U.S. and Canada) were $808 million. Effexor sales were $621 million. Prevnar/Prevenar 13 and Prevnar/Prevenar 7 sales were $569 million and $331 million, respectively.